TABLE 3.
Definition of PRD (people with rheumatic diseases) and immunomodulatory treatment
| PRD include, but are not limited to, those diagnosed with: |
| 1. Chronic inflammatory arthritides (eg rheumatoid arthritis, psoriatic arthritis, spondyloarthritides, juvenile idiopathic arthritis, adult onset Still’s disease) |
| 2. Connective tissue diseases (eg systemic lupus erythematosus, immune‐mediated inflammatory myositis, Sjӧgren’s syndrome, systemic sclerosis) |
| 3. Primary systemic vasculitides |
| 4. Autoinflammatory diseases |
| Immunomodulatory drugs considered for this guidance include: |
| 1. Conventional synthetic disease modifying anti‐rheumatic drugs (DMARDs) (methotrexate, sulphasalazine, leflunomide, hydroxychloroquine) |
| 2. Biologic DMARDs (anti‐tumor necrosis factor, tocilizumab, rituximab, abatacept, secukinumab, ixekizumab, anakinra, belimumab) |
| 3. Targeted synthetic DMARDs (tofacitinib, baricitinib, upadacitinib a ) |
| 4. Immunosuppressive drugs (cyclophosphamide, mycophenolate mofetil, azathioprine, cyclosporin A, tacrolimus) |
| 5. Glucocorticoids |
a
Not included in any of the searched literature on vaccines, hence recommendation is by extrapolation.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.